Satellos Bioscience Inc. (MSCLF) Form 6-K — May 15, 2026
Satellos Bioscience reported a Q1 2026 net loss of $9.8 million, driven by increased R&D spend of $7.3 million on its lead candidate SAT-3247 for Duchenne muscular dystrophy. The company completed a 12-for-1 share consolidation in January 2026 and began trading on Nasdaq under ticker MSLE in February. Liquidity remains strong with $69.9 million in cash and short-term investments, bolstered by a February 2026 equity offering that raised $51.9 million net. Management states this capital is sufficient to fund operations for the next 12 months without further financing.
Key figures
- Total Assets
- 75226000
- Cash Position
- 18697000
- Shares Outstanding
- 20831190
- Ga Expenses
- 2733000
- Rd Expenses
- 7310000
- Offering Price
- 10.1
- Shares Offered
- 5168019
- Total Liquidity
- 69911000
- Offering Net Proceeds
- 51901000
- Short Term Investments
- 51214000
- Offering Gross Proceeds
- 57197000
- Pre Funded Warrants Issued
- 495049
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.